Answers are grounded in this paper and cite their sources.
The advent of COVID-19, has posed a risk that human respiratory samples containing human influenza viruses may also contain SARS-CoV-2. This potential risk may lead to SARS-CoV-2 contaminating conventional influenza vaccine production platforms as respiratory samples are used to directly inoculate embryonated hen's eggs and continuous cell lines that are used to isolate and produce influenza vaccines. We investigated the ability of these substrates to propagate SARS-CoV-2 and found that neither could support SARS-CoV-2 replication.
No takes yet. Share an insight, caveat, or question.
Barr et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: